ARTICLE | Top Story

Auspex jumps on Phase III Huntington's data

December 17, 2014 2:16 AM UTC

Auspex Pharmaceuticals Inc. (NASDAQ:ASPX) surged $15.91 (63%) to $41.00 in after-hours trading after topline data late Tuesday showed its SD-809 met the primary endpoint of improving chorea (sudden, rapid uncontrolled movements) associated with Huntington's disease in the Phase III First-HD trial. The company plans to submit an NDA in 1H15.

Auspex said the deuterium-substituted analog of tetrabenazine, a vesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor, produced a 4.4 point improvement in the Total Maximal Chorea (TMC) score of the Unified Huntington's Disease Rating Scale (UHDRS) from baseline to 12 weeks vs. a 1.9 point improvement in the placebo arm (p<0.0001). ...